Chronic Myeloid Leukemia Beyond BCR::ABL1 Inhibition: Resistance Mechanisms and Emerging Therapeutic Modalities
The BCR::ABL1 fusion oncoprotein is the molecular hallmark and principal oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) have transformed CML into a largely manageable chronic disease, yet acquired resistance, persistence of leukemic stem cells (LSCs), and disease progression remai...